AstraZeneca: Vaxzevria as booster can increase antibody levels against Omicron
- FDA Approves Expanded Injectable Treatment Formula for Smallpox-Monkeypox
- UK and Netherlands follow Belgium to implement “monkeypox quarantine”
- European EMA removes about 100 generic drugs
- EU approves AstraZeneca’s COVID-19 vaccine as booster shot
- First injection of cancer-killing oncolytic virus into human patient
- First monkeypox quarantine order: Belgium requires to self-isolate for 21 days
AstraZeneca: Vaxzevria as booster can increase antibody levels against Omicron
- Unexplained acute hepatitis in children may be related to COVID superantigens
- How long can the patient live after heart stent surgery?
- Keytruda: The 5-year survival rate for advanced lung cancer doubled!
- Amylyx released the latest statistical analysis of new ALS drugs after being opposed by FDA panel last month
- Celine Dion is paralyzed due to muscle cramps: What are Muscle Cramps?
- Taiwan death from COVID-19 vaccination exceeds death from COVID-19
- The world top 5 best-selling drugs in 2020
AstraZeneca: Latest data show Vaxzevria as booster can increase antibody levels against Omicron.
AstraZeneca (AZN.US) said on Thursday that its latest preliminary data from its COVID-19 vaccine Vaxzevria showed significant antibody levels to Omicron and other variants, including Beta, Delta, Alpha and Gamma when Vaxzevria was given as a third booster dose Increase.
AstraZeneca said the booster shot boosted antibody responses in people previously vaccinated with Vaxzevria or the mRNA vaccine.
The company added that, given the urgent need for booster shot, the company will submit this data to global regulators.
Andrew Pollard, director of the Oxford Vaccine Group, said in a statement: “These important studies show that a third dose of Vaxzevria can significantly boost immunity to Covid-19 following two doses of the vaccine, or following mRNA or inactivated vaccines. “
It is understood that Vaxzevria, which was co-developed by researchers at AstraZeneca and the University of Oxford, was found to be effective against the Omicron variant by three doses of Vaxzevria in a laboratory study last month.
Separately, in December, a large UK trial found that AstraZeneca’s booster shot increased antibody levels in people vaccinated with AstraZeneca’s vaccine or Pfizer’s (PFE.US) vaccine.
Still, the study concluded that the Pfizer and Moderna (MRNA.US) vaccines work best as boosters.
AstraZeneca: Vaxzevria as booster can increase antibody levels against Omicron
(source:internet, reference only)
Disclaimer of medicaltrend.org
